Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Operating Leases (2023 - 2025)

Historic Operating Leases for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $180000.0.

  • Zenas BioPharma's Operating Leases changed N/A to $180000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $180000.0, marking a year-over-year change of. This contributed to the annual value of $218000.0 for FY2024, which is 1517.51% down from last year.
  • Per Zenas BioPharma's latest filing, its Operating Leases stood at $180000.0 for Q3 2025.
  • In the past 5 years, Zenas BioPharma's Operating Leases ranged from a high of $317000.0 in Q1 2025 and a low of $180000.0 during Q3 2025
  • Its 3-year average for Operating Leases is $237400.0, with a median of $218000.0 in 2024.
  • The largest annual percentage gain for Zenas BioPharma's Operating Leases in the last 5 years was 1517.51% (2024), contrasted with its biggest fall of 1517.51% (2024).
  • Zenas BioPharma's Operating Leases (Quarter) stood at $257000.0 in 2023, then decreased by 15.18% to $218000.0 in 2024, then fell by 17.43% to $180000.0 in 2025.
  • Its Operating Leases was $180000.0 in Q3 2025, compared to $215000.0 in Q2 2025 and $317000.0 in Q1 2025.